Anebulo Pharmaceuticals, Inc. (ANEB)

Market Cap	13.52M -86.1%
Revenue (ttm)	n/a
Net Income	-7.98M
EPS	-0.19
Shares Out	40.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	0.3600
Previous Close	0.3315
Day's Range	0.3600 - 0.3600
52-Week Range	0.0004 - 2.8500
Beta	-1.83
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 25, 2026

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headqu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: ANEB

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 15, 2026

Data Sources Report a data error